Advisory Research Inc Chinook Therapeutics, Inc. Transaction History

Advisory Research Inc

  • $499 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$21.53 - $26.8 $3,746 - $4,663
-174 Reduced 0.56%
30,927 $715,000
Q4 2022

Feb 13, 2023
BUY
$18.63 - $27.35 $41,116 - $60,361
2,207 Added 7.64%
31,101 $814,000
Q3 2022

Nov 14, 2022
BUY
$17.51 - $23.37 $505,933 - $675,252
28,894 New
28,894 $568,000

Others Institutions Holding KDNY

# of Institutions
5
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Advisory Research Inc Portfolio

Follow Advisory Research Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Research Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email